A recent study that found there has been a massive increase in type 2 diabetes cases worldwide since 1990 is an indication ...

Study conducted by NCD Risk Factor Collaboration (NCD-RisC) and WHO. Findings part of first global analysis of trends in both ...

He said the "War on Sugar” campaign is a government initiative to reduce the intake of sugar among the people as a measure to tackle non-communicable diseases (NCDs) such as diabetes.

Performing computerized analysis to identify patients receiving target drugs that ... a source of comparison doses but were used to compare the efficiency and effectiveness of chart reviewers ...

The biggest surprise in the quarter came from weight-loss drug Zepbound and diabetes drug Mounjaro, which together came in nearly $900 million below estimates. Lilly’s success story “has been ...

GLP-1RAs may lead to rapid weight loss in type 1 diabetes, complicating insulin management. Use of these drugs in type 1 diabetes has grown driven by the need to address obesity, heart, and kidney ...

Alternatively, they may adjust your medications to help prevent your blood pressure from dropping too much. Also, insulin and other diabetes medications that mimic insulin (including sulfonylureas) ...

People with type 2 diabetes who stick to a low-carb diet may be able to stop taking medication, suggests a new study. American researchers found low-carbohydrate diets may improve the beta-cell ...

Participants received their type 2 diabetes diagnosis within the previous 10 years and were being treated with diet or medications but were not using insulin. Researchers had participants ...

The diabetes drug semaglutide, also known as Ozempic, has a positive effect on patients with chronic kidney disease and obesity. The amount of protein in their urine decreased, as did the degree ...

Surprisingly, new research suggests that taking GLP-1RA is not associated with an increased risk of AKI in patients receiving anti-cancer therapies. The findings were presented at ASN Kidney Week ...

This was in comparison with the seven other similar diabetes drugs. Results were consistent even when people’s obesity status, biological sex, and age were considered. However, the study authors ...